GSK to Acquire RAPT Therapeutics for $2.2 Billion, Offering $58.00 Per Share in Cash

summarizeSummary

RAPT Therapeutics has entered a definitive agreement to be acquired by GSK for $58.00 per share in cash, valuing the company at an estimated $2.2 billion.

check_boxKey Events

• Acquisition Agreement Announced

  GSK plc has entered a definitive agreement to acquire RAPT Therapeutics, Inc. through a cash tender offer.

• Offer Price and Valuation

  GSK will pay RAPT shareholders $58.00 per share in cash, totaling an estimated aggregate equity value of $2.2 billion.

• Significant Premium

  The offer price of $58.00 per share represents a premium to the current stock price and is substantially above the company's 52-week high of $42.39.

• Strategic Asset Acquired

  The acquisition includes ozureprubart, a long-acting anti-IgE monoclonal antibody in Phase IIb clinical development for prophylactic protection against food allergens.

auto_awesomeAnalysis

This filing announces a definitive agreement for GSK to acquire RAPT Therapeutics, representing a fundamental change in the company's future. The acquisition price of $58.00 per share in cash is a significant premium to the current stock price of $57.44 and substantially above the company's 52-week high of $42.39. This transaction provides immediate and substantial value to RAPT shareholders. The strategic rationale for GSK is to gain global rights to ozureprubart, a promising anti-IgE antibody in Phase IIb development for food allergies, which complements GSK's existing pipeline in respiratory, immunology, and inflammation. Investors should expect the stock price to converge with the offer price, assuming the deal closes as expected in Q1 2026.